|

JNJ-79635322 Clinical Trials

5 actively recruiting trials across 1 location

Other4 trials

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
Phase 2

Duarte, California1 trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

City of Hope

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.